Índice

• Éditorial

  • ·Vasculitides: Roads traveled and avenue to pursue

    Página :491-492

    Loïc Guillevin

    Resumen Resumen Esquema Esquema

• Lectures

  • ·L1. Pathogenesis of ANCA-associated vasculitis: Observations, theories and speculations

    Página :493-498

    J. Charles Jennette, Ronald J. Falk

    Resumen Resumen Esquema Esquema  
  • ·L2. Neutrophil transmigration in vivo: Mechanisms, dynamics and contribution to dissemination of systemic inflammation

    Página :498-499

    Sussan Nourshargh

    Resumen Resumen Esquema Esquema  
  • ·L3. Are mononuclear cells predominant actors of endothelial damage in vasculitis?

    Página :499-503

    Wayel H. Abdulahad, Alexandre W.S. De Souza, Cees G.M. Kallenberg

    Resumen Resumen Esquema Esquema
  • ·L4. Eosinophils: How they contribute to endothelial damage and dysfunction

    Página :503-507

    Florence Roufosse

    Resumen Resumen Esquema Esquema
  • ·L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

    Página :507-510

    Jean-François Cordier, Vincent Cottin, Loïc Guillevin, Elisabeth Bel, Paolo Bottero, Klaus Dalhoff, Marc Humbert, Romain Lazor, Renato A. Sinico, Pasupathy Sivasothy, Michael E. Wechsler

    Resumen Resumen Esquema Esquema
  • ·L6. Eosinophilic granulomatosis with polyangiitis: Future therapies

    Página :510-512

    Frank Moosig

    Resumen Resumen Esquema Esquema
  • ·L7. Animal models of PR3-ANCA vasculitis: Approaches and controversies

    Página :512-515

    Mark A. Little

    Resumen Resumen Esquema Esquema
  • ·L8. Animal models of ANCA associated vasculitis: The contribution of autoantibodies and autoreactive T cells

    Página :515-517

    Peter Heeringa

    Resumen Resumen Esquema Esquema
  • ·L9. The role of genetic background in an animal model of ANCA-associated vasculitis

    Página :517-520

    Hong Xiao

    Resumen Resumen Esquema Esquema  
  • ·L10. Animal models of ANCA-associated vasculitis: Effector mechanisms and experimental therapies

    Página :520-523

    Adrian Schreiber

    Resumen Resumen Esquema Esquema
  • ·L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: Therapeutic options

    Página :523-527

    Patrice Cacoub, Benjamin Terrier, David Saadoun

    Resumen Resumen Esquema Esquema
  • ·L12. Rheumatoid arthritis vasculitis

    Página :527-530

    Xavier Puéchal

    Resumen Resumen Esquema Esquema
  • ·S1. Rituximab for ANCA-associated vasculitis: The experience in the United States

    Página :530-532

    Jeremy M. Clain, Ulrich Specks

    Resumen Resumen Esquema Esquema
  • ·S2. Rituximab for ANCA-associated vasculitis: The UK experience

    Página :532-534

    David Jayne

    Resumen Resumen Esquema Esquema
  • ·S3. Rituximab for ANCA-associated vasculitides: The French experience

    Página :534-536

    Pierre Charles, Loïc Guillevin

    Resumen Resumen Esquema Esquema
  • ·L13. Apoptosis, Apoptotic cell clearance and resolution of inflammation

    Página :536-537

    Adriano G. Rossi

    Resumen Resumen Esquema Esquema
  • ·L14. Immunomodulatory properties of apoptotic cells

    Página :537-543

    Sylvain Perruche, Philippe Saas

    Resumen Resumen Esquema Esquema  
  • ·L15. EULAR/ACR 2012 classification criteria for polymyalgia rheumatica

    Página :543-546

    Eric L. Matteson, EULAR/ACR Study Group for Development of Classification Criteria for Polymyalgia Rheumatica

    Resumen Resumen Esquema Esquema
  • ·L16. The specificities of pediatric vasculitis classification

    Página :546-550

    Cigdem Yildiz, Seza Ozen

    Resumen Resumen Esquema Esquema
  • ·L17. What can we expect from the revised Chapel Hill consensus conference nomenclature of vasculitis?

    Página :550-555

    J. Charles Jennette

    Resumen Resumen Esquema Esquema  
  • ·L18. Granuloma formation in granulomatosis with polyangiitis

    Página :555-558

    Konstanze Holl-Ulrich

    Resumen Resumen Esquema Esquema  
  • ·L19. Lymphoid neogenesis in vascular chronic inflammation

    Página :558-560

    Antonino Nicoletti, Jamila Khallou-Laschet, Kevin Guedj, Marc Clement, Anh-Thu Gaston, Marion Morvan, Charles-Antoine Dutertre, Jean-Baptiste Michel, Olivier Thaunat, Giuseppina Caligiuri

    Resumen Resumen Esquema Esquema
  • ·L20. Memory T-cells in vasculitis

    Página :560-563

    Peter Lamprecht

    Resumen Resumen Esquema Esquema
  • ·L21. Kidneys in ANCA-associated vasculitis: What to learn from biopsies?

    Página :563-565

    Chinar Rahmattulla, Annelies E. Berden, Ingeborg M. Bajema

    Resumen Resumen Esquema Esquema
  • ·L22. Crescent formation: Unraveling local mediators that break glomerular epithelial cell tolerance to immune injury

    Página :565-568

    Carole Hénique, Cécile Fligny, Pierre-Louis Tharaux

    Resumen Resumen Esquema Esquema  
  • ·L23. Renal transplantation in ANCA-associated vasculitis

    Página :568-571

    Mårten Segelmark

    Resumen Resumen Esquema Esquema
  • ·L24. Local treatments of subglottic and tracheal stenoses in granulomatosis with polyangiitis (Wegener’s)

    Página :571-574

    Niels Rasmussen

    Resumen Resumen Esquema Esquema  
  • ·L25. Medical treatment of subglottic stenosis in granulomatosis with polyangiitis (Wegener’s)

    Página :575-576

    Paul A. Monach

    Resumen Resumen Esquema Esquema
  • ·L26. How antigens influence the disease: An immunologist point of view

    Página :577-579

    Meghan E. Free, Dominic J. Ciavatta, Ronald J. Falk

    Resumen Resumen Esquema Esquema
  • ·L27. Antibodies versus phenotypes: A clinician’s view

    Página :579-582

    David Jayne

    Resumen Resumen Esquema Esquema
  • ·L28. Relevance of detection techniques for ANCA testing

    Página :582-584

    Csernok Elena

    Resumen Resumen Esquema Esquema
  • ·L29. Relevance of anti-LAMP-2 in vasculitis: Why the controversy

    Página :584-588

    Renate Kain

    Resumen Resumen Esquema Esquema
  • ·L30. Assessment of vasculitis extent and severity

    Página :588-589

    Nicolò Pipitone, Giulia Pazzola, Francesco Muratore, Carlo Salvarani

    Resumen Resumen Esquema Esquema
  • ·L31. A GWAS in ANCA-associated vasculitis: Will genetics help re-define clinical classification?

    Página :589-591

    Paul A. Lyons, Kenneth G.C. Smith

    Resumen Resumen Esquema Esquema
  • ·L32. ANCA vasculitis over the world. What do we learn from country differences?

    Página :591-593

    Richard A. Watts, David Gi Scott

    Resumen Resumen Esquema Esquema
  • ·L33. Neutrophil in immunity: A key modulator

    Página :594-595

    Marco A. Cassatella

    Resumen Resumen Esquema Esquema
  • ·L34. Neutrophils in ANCA-associated vasculitis: Still under investigation

    Página :595-597

    Véronique Witko-Sarsat

    Resumen Resumen Esquema Esquema
  • ·L35. Fc receptors and cell activation

    Página :598-599

    Renato C. Monteiro

    Resumen Resumen Esquema Esquema
  • ·L36. Evidence-based clinical science and art in the diagnosis of central nervous system vasculitis

    Página :600-602

    Leonard H. Calabrese

    Resumen Resumen Esquema Esquema
  • ·L37. Reversible cerebral vasoconstriction syndrome: Distinction from CNS vasculitis

    Página :602-604

    Anne Ducros

    Resumen Resumen Esquema Esquema
  • ·L38. How to treat primary vasculitis of the central nervous system

    Página :605-607

    Christian Pagnoux, Hubert de Boysson

    Resumen Resumen Esquema Esquema
  • ·L39. Fulminant anca vasculitis

    Página :607-609

    Alexandre Karras, Christian Jacquot, Eric Thervet

    Resumen Resumen Esquema Esquema
  • ·L41. Perspectives on the treatment of giant cell arteritis

    Página :609-612

    Carol A. Langford

    Resumen Resumen Esquema Esquema
  • ·L42. Morbidity in patients with ANCA-associated vasculitis

    Página :612-616

    Lorraine Harper

    Resumen Resumen Esquema Esquema
  • ·L43. Seropositive and negative ANCA-associated vasculitis, anti-MPO and PR3-vasculitis: Different outcomes?

    Página :616-619

    Julia U. Holle

    Resumen Resumen Esquema Esquema
  • ·L44. Management of relapses in vasculitis

    Página :619-622

    Luc Mouthon

    Resumen Resumen Esquema Esquema
  • ·L45. Aortitis, retroperitoneal fibrosis, and IgG4-related disease

    Página :622-625

    John H. Stone

    Resumen Resumen Esquema Esquema  
  • ·L46. Novel forms of clinical vasculitis: Anti-GBM vasculitis (Goodpasture’s disease)

    Página :625-628

    Stephen P. McAdoo, Charles D. Pusey

    Resumen Resumen Esquema Esquema
  • ·L47. Single-organ vasculitis: Conceptual and practical considerations

    Página :628-634

    Alfred Mahr, Maxime Battistella, Jean-David Bouaziz, Séverin Chaigne-Delalande

    Resumen Resumen Esquema Esquema  
  • ·L48. The challenges in assessing Takayasu arteritis

    Página :634-635

    Paul Bacon, Ramnath Misra

    Resumen Resumen Esquema Esquema
  • ·L49. Percutaneous interventions in Takayasu arteritis

    Página :635-637

    George Joseph

    Resumen Resumen Esquema Esquema
  • ·L50. The future of international clinical trials in vasculitis

    Página :637-641

    Peter A. Merkel

    Resumen Resumen Esquema Esquema
  • ·L51. From immunosuppression to selective treatments: The benefit–risk ratio

    Página :641-643

    Loïc Guillevin

    Resumen Resumen Esquema Esquema
  • ·L52. Vasculitis treatment: Is it time to change the standard of care for ANCA-associated vasculitis?

    Página :643-650

    Gary S. Hoffman

    Resumen Resumen Esquema Esquema  

• Abstracts

  • ·Calprotectin amplifies the inflammatory response

    Página :651

    R. Pepper, S. Hamour, H.H. Wang, T. Vogl, T. Cook, C. Pusey, A. Salama

    
  • ·Proteinase 3induces shape change in platelets through activation of the Rho/Rho-kinase signaling pathway

    Página :651

    X. Peng, T. Kurz, C. Brommesson, M. Grenegård, M. Segelmark

    
  • ·Identification of target antigens of anti-endothelial cell antibodies in patients with ANCA-associated systemic vasculitis: A proteomic approach

    Página :651-652

    A. Régent, H. Dib, G. Bussone, N. Tamas, C. Federici, C. Broussard, L. Guillevin, L. Mouthon

    Resumen Resumen Esquema Esquema
  • ·Proteinase 3 (PR3) is a phosphatidylserine-binding protein that can bind microparticles: Relevance in the context of granulomatosis with polyangiitis (GPA)

    Página :652

    M. Pederzoli-Ribeil, F. Angelot, A. Millet, C. Kantari, N. Reuter, L. Mouthon, P. Frachet, P. Saas, V. Witko-Sarsat

    
  • ·Orthotopic heart transplantation in eosinophilic granulomatosis with polyangiitis

    Página :652-653

    M. Groh, G. Masciocco, E. Kirchner, A. Kristen, G. Bortman, S. Varnous, M. Rosenberg, A. D’armini, C. Pellegrini, A. Brucato, G. Gregorini, M. Frigerio, J.J. Scali, L. Calabrese, L. Guillevin

    Resumen Resumen Esquema Esquema
  • ·Cluster analysis to explore subclassification of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)

    Página :653

    T. Neumann, F. Moosig, A. Vaglio, J. Zwerina, P. Bremer, A. Gioffredi, J. Grosskreutz, C. Kroegel, F. Maritati, M. Resche-Rigon, A. Mahr

    
  • ·Spleen tyrosine kinase (SYK) inhibition in experimental autoimmune glomerulonephritis (EAG)

    Página :653-654

    S.P. Mcadoo, J. Reynolds, J. Smith, G. Bhangal, E. Masuda, T.H. Cook, C.D. Pusey, F. Tam

    Resumen Resumen Esquema Esquema  
  • ·Serum biomarkers signature identifies patients with overt B-cell non-Hodgkin lymphoma associated with mixed cryoglobulinemia in chronic HCV infection

    Página :654

    B. Terrier, W. Chaara, G. Geri, D. Saadoun, M. Rosenzwajg, D. Sène, A. Six, D. Klatzmann, P. Cacoub

    
  • ·Characterization of drug-induced ANCA vasculitis at Massachusetts’s general hospital (MGH): 1989–2012

    Página :654-655

    W. Pendergraft, M. Mcgrath, A. Murphy, P. Murphy, K. Laliberte, J. Niles

    Resumen Resumen Esquema Esquema  
  • ·High genetic diversity in nasal Staphylococcus aureus isolates from Granulomatosis with Polyangiitis (GPA) patients

    Página :655

    M.M. Van Timmeren, C. Glasner, T. Stobernack, T.F. Omansen, E.C. Raangs, J.W. Rossen, J.P. Arends, G.A. Kampinga, W.J.B. Van Wamel, A. Rutgers, C.A. Stegeman, C.G.M. Kallenberg, P. Heeringa, J.M. Van Dijl

    
  • ·Neutrophils in ANCA vasculitis – old and apathetic

    Página :655-656

    T. Hellmark, Å. Pettersson, D. Selga, A. Bengtsson, Å. Johansson

    Resumen Resumen Esquema Esquema
  • ·Phagocytosis of apoptotic cells expressing PR3 impaired macrophage anti-inflammatory reprogramming

    Página :656

    A. Millet, J. Mocek, M. Pederzoli-Ribeil, F. Cormier, V. Baud, V. Witko-Sarsat

    
  • ·ANCA disease patients have defective Treg function exacerbated by expansion of a suppression-resistant effector population

    Página :656

    M. Free, D. Bunch, J.A. Mcgregor, C. Poulton, B. Jones, E. Berg, S. Hogan, Y. Hu, G. Preston, C. Jennette, R. Falk, M. Su

    
  • ·Unraveling the identity of FoxP3+ regulatory T cells in GPA-patients

    Página :656-657

    W.H. Abdulahad, C.A. Stegeman, M.G. Huitema, P.C. Limburg, A. Rutgers, P. Heeringa, C.G.M. Kallenberg

    Resumen Resumen Esquema Esquema
  • ·Performance of the ACR classification criteria as diagnostic criteria for granulomatosis with polyangiitis (GPA) (Wegener’s) in a respiratory referral centre

    Página :657

    F. Contreras-Rodríguez, J. Rojas-Serrano, L.F. Flores-Suárez

    
  • ·Use of the CHCC 2012 definitions in the classification of AAV using the EMA algorithm

    Página :657

    R. Abdulkader, D.G.I. Scott, J. Mooney, S.E. Lane, R.A. Watts

    
  • ·B regulatory cells are numerically but not functionally impaired in AAV

    Página :658

    S.K. Todd, R.J. Pepper, A. Tanna, C. Mauri, A.D. Salama

    
  • ·Nasal mucosa provides a niche for autoreactive plasma cells in granulomatosis with polyangiitis (Wegener’s)

    Página :658

    J. Voswinkel, C. Brieske, E. Csernok, W. Gross, K. Holl-Ulrich, A. Mueller

    
  • ·Dutch transplantation in vasculitis (DUTRAVAS)-study: Update on the outcome of renal transplantation in ANCA-associated vasculitis (AAV) patients in the Netherlands

    Página :658-659

    A. Göçeroğlu, C. Rahmattulla, A.E. Berden, M. Reinders, M.C.R.F. Van Dijk, A.A.E. De Joode, C.J. Peutz-Kootstra, M.H.L. Christiaans, I. Noorlander, R. Goldschmeding, A.D. Van Zuilen, E.J. Steenbergen, L.B. Hilbrands, L. Harper, M.A. Little, E.C. Hagen, J.A. Bruijn, I.M. Bajema

    Resumen Resumen Esquema Esquema
  • ·Complement pathways activation in pauci-immune necrotizing glomerulonephritis with ANCA

    Página :659

    M.L. Figuères, F. Fakhouri, A. Moreau, Y. Chaabouni, L.H. Noel

    
  • ·Tracheal and bronchial stenoses in granulomatosis with polyangiitis (Wegener) (GPA)

    Página :659-660

    B. Terrier, P. Cohen, X. Puéchal, L. Mouthon, L. Guillevin, For the French Vasculitis Study Group (FVSG)

    Resumen Resumen Esquema Esquema
  • ·Rituximab therapy for granulomatous poliangeitis (Wegener’s granulomatosis) with refractory granulomatous manifestations

    Página :660

    R. Solans, F. Martinez-Valle, A. Segarra, M. Ramentol, I. Agraz, J.A. Bosch

    
  • ·Upper airway gene expression profiling in granulomatosis with polyangiitis

    Página :660-661

    P. Grayson, K. Steiling, P. Monach, M. Platt, J. Xiao, X. Zhang, Y. Alekseyev, S. Moni, A. Spira, P. Merkel

    Resumen Resumen Esquema Esquema
  • ·Both histone methylation and acetylation contribute to the aberrant upregulation of proteinase 3 (PR3) and myeloperoxidase (MPO) genes in patients with ANCA disease

    Página :661

    J. Yang, C.J. Poulton, C. Henderson, J.C. Jennette, G. Preston, R. Falk, D. Ciavatta

    
  • ·Reclassifying ANCA-associated vasculitis using the EUVAS algorithm: Epidemiology and survival from the NORVASC register

    Página :661-662

    R. Abdulkader, J. Mooney, C. Sheehy, C. Mukhtyar, D.G.I. Scott, R.A. Watts

    Resumen Resumen Esquema Esquema
  • ·A myelopoiesis gene signature during remission in ANCA-associated vasculitis reflects ongoing prednisolone therapy and does not seem to predict relapses

    Página :662

    T. Kurz, M. Weiner, C. Skoglund, S. Basnet, P. Eriksson, M. Segelmark

    
  • ·ENT involvement is related to better renal function in patients with ANCA-associated vasculitis

    Página :662-663

    C. Rahmattulla, R.A.F. De Lind Van Wijngaarden, A.E. Berden, H.A. Hauer, O. Floßmann, D.R.W. Jayne, G. Gaskin, N. Rasmussen, L.H. Noël, F. Ferrario, R. Waldherr, C.D. Pusey, E.C. Hagen, J.A. Bruijn, I.M. Bajema

    Resumen Resumen Esquema Esquema
  • ·Clinical evaluation of a rapid immunofluorescence test (IIFT) for diagnosis of ANCA-associated vasculitis

    Página :663

    L. Bianchi, S. Glionna, B. Trezzi, C. Farina, R.A. Sinico

     
  • ·Prevalence of anti-neutrophil cytoplasmic antibodies in infective endocarditis: An analysis of 109 cases

    Página :663-664

    A. Mahr, F. Batteux, S. Tubiana, M. Wolff, C. Goulvestre, T. Papo, I. Klein, F. Vrtovsnik, B. Iung, X. Duval

    Resumen Resumen Esquema Esquema
  • ·Recurrent acquired ANCA-positive agranulocytosis after cocaine exposure: A chronic disease?

    Página :664

    F. Schieppati, G. Gregorini, U. Specks, S.M. Eder, A.M. Hummel, G. Rossi

    
  • ·ANCA epitope specificity determines pathogenicity, detectability and clinical predictive value

    Página :664

    A. Roth, J. Ooi, J. Hess, M. Van Timmeren, E. Berg, C. Poulton, J. Mcgregor, M. Burkart, S. Hogan, Y. Hu, W. Winnik, P. Nachman, C. Stegeman, J. Niles, P. Heeringa, M. Free, R. Kitching, S. Holdsworth, C. Jennette, G. Preston, R. Falk

    
  • ·Characteristics and outcomes of patients with ANCA-associated vasculitis in the Czech population

    Página :664-665

    Z. Hruskova, E. Jancova, V. Lanska, J. Svojanovsky, J. Klaboch, P. Nemec, K. Zamboch, M. Kodeda, V. Hanzal, P. Nemejc, V. Tesar, On Behalf Of The Czech National Clinical Registry Of Aav 1

    Resumen Resumen Esquema Esquema
  • ·Premature ovarian failure in women with ANCA-associated vasculitis

    Página :665

    J. Tuin, J.S. Sanders, A. Hoek, C.A. Stegeman

    
  • ·Infection risk in ANCA-associated vasculitis

    Página :665-666

    M. Morgan, A. Richter, J. Flint, M. Drayson, C. Yiannakis, D. Goldblatt, L. Harper

    Resumen Resumen Esquema Esquema
  • ·A risk score for predicting short-term incidence of death or relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis

    Página :666

    C. Maldini, M. Resche-Rigon, D. Jayne, K. Westman, A. Mahr

    
  • ·Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA), polyarteritis nodosa (PAN) and microscopic polyangiitis (MPA) with no initial Five-Factor Score-defined poor-prognosis factors (FFS = 0): Baseline factors associated with cytotoxic agent and immunomodulator prescription

    Página :666

    M. Samson, X. Puéchal, H. Devilliers, C. Ribi, P. Cohen, B. Bienvenu, C. Pagnoux, L. Mouthon, L. Guillevin

    
  • ·Computerized interstitial fibrosis quantification is the most powerful histological predictor of renal outcome in ANCA-associated vasculitis

    Página :667

    C. Levi, V. Meas-Yedid, C. Daniliuc, J.C. Olivo-Marin, E. Guiard, L. Mouthon, M. Roland, L. Guillevin, C. Jacquot, A. Karras, E. Thervet

    
  • ·The necessity of the addition of interstitial pathological parameters on the glomerular histological classification to predict the long-term outcome in MPO-ANCA-associated RPGN cohort in Japan

    Página :667

    E. Muso, T. Endo, M. Itabashi, Y. Iwasaki, H. Kakita, Y. Tateishi, T. Komiya, T. Ihara, W. Yumura, T. Sugiyama, K. Joh, K. Suzuki

    
  • ·Long-term outcome in patients with both ANCA and GBM positivity

    Página :667-668

    A. Tanna, S. Mcadoo, F. Tam, T. Cairns, M. Griffith, A. Salama, J. Levy, C. Pusey

    Resumen Resumen Esquema Esquema  
  • ·Granulomatosis with polyangiitis (Wegener’s) is associated with HLA-DPB1*04 and EMA6A gene variants. Evidence from a genome-wide analysis

    Página :668

    G. Xie, D. Roschandel, R. Sherva, P. Monach, Y. Lu, T. Kung, K. Carrington, S. Carette, P. Dellaripa, J. Edberg, G. Hoffman, N. Khalidi, C. Langford, A. Mahr, E.W. St. Clair, P. Seo, U. Specks, R. Spiera, J. Stone, S. Ytterberg, S. Raychaudhuri, P. De Bakker, L. Farrer, C. Amos, P. Merkel, K. Siminovitch

    
  • ·ANCA-associated vasculitis in Hispanics: An unrecognized severity

    Página :668-669

    A. Sreih, R. Mandhadi, J. Block

    Resumen Resumen Esquema Esquema
  • ·Genetic regulation of CD177 – A receptor presenting anti-neutrophil cytoplasmic antigen proteinase 3

    Página :669

    C. Eulenberg, S. Bähring, F. Luft, R. Kettritz

    
  • ·ANCA disease patients with increased expression of autoantigen genes produce an alternative PR3 transcript and synthesize autoantigen proteins

    Página :669

    E. Alderman, A. Badwar, A. Muthigi, C. Allred, J. Yang, O. Lardinois, J.C. Jenette, G. Preston, R. Falk, D. Ciavatta

    
  • ·Long-term outcomes of patients with reversible cerebral vasoconstriction syndrome (RCVS)

    Página :670

    R. Hajj-Ali, S. John, L. Calabrese, M. Stillman, S. Tepper, K. Uchino

    
  • ·Recognizing childhood inflammatory brain diseases in Canada

    Página :670

    M. Twilt, S. Sheikh, T. Cellucci, G. Chedeville, A. Kirton, A. Mineyko, H. Schmelig, D. Pohl, J. Roth, D. Cabral, A. Huber, A. Rosenberg, N. Schiff, S. Benseler

    
  • ·Factors predictive of prognosis in renal AAV – A study of 104 patients in a single UK centre

    Página :670-671

    A. Tanna, G. Laura, F. Tam, T. Cairns, M. Griffith, R. Tarzi, J. Levy, A. Salama, G. Gaskin, T. Cook, C. Pusey

    Resumen Resumen Esquema Esquema  
  • ·Prognosis of patients with ANCA-associated glomerulonephritis (GN) presenting with severe renal failure

    Página :671

    T. Lee, A. Gasim, J.A.G. Mcgregor, V.K. Derebail, C.J. Poulton, S. Lionaki, S.L. Hogan, J.C. Jennette, R.J. Falk, P.H. Nachman

    
  • ·Diffuse alveolar haemorrhage (DAH) in levamisole-adultered cocaine abuser resolved by rFVIIa infusion

    Página :671-672

    E. Pecci, G. Gregorini, P. Sinigaglia, G. Bozzola, G. Tassi, P. Ferremi, N. Latronico

    Resumen Resumen Esquema Esquema
  • ·ANCA-associated vasculitis (AAV) and thrombotic michroangiopathies (TMA): A retrospective histological study

    Página :672

    L. Manenti, E. Gnappi, L. Signorini, F. Pilato, A. Vaglio, C. Buzio

     
  • ·The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK

    Página :672-673

    J. Robson, A. Kiran, J. Maskell, A. Hutchings, N. Arden, B. Dasgupta, W. Hamilton, D. Culliford, A. Emin, R. Luqmani

    Resumen Resumen Esquema Esquema
  • ·Risk of cardiovascular disease early and late after a diagnosis of giant cell arteritis

    Página :673

    G. Tomasson, C. Peloquin, A. Mohammad, T. Love, Y. Zhang, H.K. Choi, P.A. Merkel

    
  • ·Large vessel vasculitis: Estimating disease activity in patients with thoracic aortic aneurysms

    Página :673

    A. Clifford, T. Clark, D. Johnston, G. Pettersson, E. Roselli, E. Soltesz, L. Svensson, G. Hoffman

    
  • ·Assessment of disease activity in large vessel vasculitis: Initial results of an international Delphi exercise

    Página :673-674

    S.Z. Aydin, H. Direskeneli, E. Matteson, P.A. Merkel

    Resumen Resumen Esquema Esquema
  • ·Outcome and prognostic factors in elderly patients with ANCA-associated vasculitis

    Página :674

    M. Weiner, S.M. Goh, A. Mohammad, Z. Hrušková, A. Tanna, A. Bruchfeld, D. Selga, Q. Ko, K. Westman, P. Eriksson, C. Pusey, V. Tesar, A. Salama, M. Segelmark

    
  • ·Factors associated with major cardiovascular events in patients with primary systemic necrotizing vasculitides: Results of a longitudinal long-term follow-up study

    Página :674-675

    B. Terrier, C. Pagnoux, G. Chironi, A. Simon, L. Mouthon, L. Guillevin

    Resumen Resumen Esquema Esquema
  • ·Outcomes in patients with granulomatosis with polyangiitis (Wegener’s) treated with short vs. long-term maintenance therapy

    Página :675

    J. Springer, B. Nutter, C. Langford, G. Hoffman, A. Villa-Forte

    
  • ·Characteristics and outcome of patients with granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis on renal replacement therapy – Data from the ERA-EDTA registry

    Página :675

    Z. Hruskova, V.S. Stel, D.R. Jayne, V. Tesar, K.J. Jager, On Behalf Of The National/Regional Renal Registry Representatives In Europe 2

    
  • ·Occupational and environmental risk factors in chronic periaortitis: A case-control study

    Página :675-676

    M.L. Urban, S. Bonini, A. Mutti, C. Buzio, A. Vaglio

    Resumen Resumen Esquema Esquema
  • ·Behçet’s disease in Budd-Chiari Syndrome

    Página :676

    A.C. Desbois, P.E. Rautou, A. Plessier, N. Belmatoug, M. Pineton De Chambrun, B. Wechsler, M. Resche-Rigon, B. Fantin, D. Valla, P. Cacoub, D. Saadoun

    
  • ·The unmet need in Behçet’s disease: Most patients are not in complete remission in the long-term follow-up

    Página :676-677

    F. Alibaz-Oner, G. Mumcu, G. Ozen, Z. Kubilay, M. Can, S. Yılmaz Oner, T. Ergun, H. Direskeneli

    Resumen Resumen Esquema Esquema  
  • ·Cutaneous vasculitis: Report of 117 cases

    Página :677

    P. Fanlo, A. Villanueva, S. Clemos, C. Perez, R. Guarch, M. Montes

    
  • ·Takayasu arteritis – An outcome study in a UK cohort

    Página :677

    T. Youngstein, J. Mason

    
  • ·Biologic agents offer an effective long-term therapeutic option for refractory Takayasu arteritis

    Página :677-678

    T. Youngstein, J. Peters, J. Mason

    Resumen Resumen Esquema Esquema
  • ·Assessment of patients with Takayasu’s arteritis in a routine clinical follow-up with Indian Takayasu Clinical Activity Score (ITAS2010)

    Página :678

    F. Alibaz-Oner, H. Direskeneli

    
  • ·A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: “MYCYC”. On behalf of the European vasculitis study group

    Página :678-679

    R. Jones, L. Harper, J. Ballarin, D. Blockmans, P. Brogan, A. Bruchfeld, M. Cid, K. Dahlsveen, J. Dezoysa, P. Lanyon, C.A. Peh, V. Tesar, A. Vaglio, M. Walsh, D. Walsh, G. Walters, D. Jayne

    Resumen Resumen Esquema Esquema
  • ·Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. A prospective study in 117 patients

    Página :679

    L. Guillevin, C. Pagnoux, A. Karras, C. Khouatra, O. Aumaitre, P. Cohen, O. Decaux, H. Desmurs-Clavel, P. Gobert, T. Quemeneur, C. Blanchard-Delaunay, P. Godmer, X. Puechal, P.L. Carron, P.Y. Hatron, N. Limal, M. Hamidou, B. Bonnotte, P. Ravaud, L. Mouthon, for the FVSG

    
  • ·Treatment of systemic necrotizing vasculitides in patients ≥ 65 years old: Results of the multicenter randomized CORTAGE trial

    Página :679-680

    C. Pagnoux, T. Quéméneur, J. Ninet, E. Perrodeau, E. Diot, X. Kyndt, B. De Wazières, J.L. Reny, X. Puéchal, P.Y. Leberruyer, O. Lidove, P. Vanhille, P. Godmer, A. Albath-Sadiki, B. Bienvenu, P. Cohen, L. Mouthon, P. Ravaud, L. Guillevin, FVSG 16

    Resumen Resumen Esquema Esquema
  • ·Randomized clinical trial of extended versus standard azathioprine maintenance therapy in newly diagnosed PR3-ANCA positive vasculitis patients at high-risk for disease relapse

    Página :680

    A.A.E. De Joode, J.S. Sanders, J.W. Cohen Tervaert, C.A. Stegeman

     

• Posters

  • ·The diagnostic value of distinguishing and reporting different perinuclear ANCA (P-ANCA) immunofluorescence patterns: A prospective study

    Página :681

    S. Perel, K. Prain, R. Wilson, R. Wong, D. Gillis, P. Hogan

    
  • ·ANCA testing in routine clinical laboratory

    Página :681-682

    I. Lochman, A. Lochmanová

    Resumen Resumen Esquema Esquema
  • ·Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis relapses? Results of a longitudinal study on 126 patients

    Página :682

    L.H. Thai, P. Charles, M. Resche-Rigon, L. Guillevin

    
  • ·Results of ANCA standardisation and their diagnostic usefulness in ANCA-associated vasculitides (AASV) in a respiratory referral centre in Mexico

    Página :682-683

    F. Contreras-Rodríguez, J. Rojas-Serrano, J.E. Figueroa-Aguirre, L.F. Flores-Suárez

    Resumen Resumen Esquema Esquema
  • ·Incidence of PR3- and MPO-ANCA autoantibody specificity changes in ANCA associated vasculitis

    Página :683

    S. Holding, M. Abuzakouk

    
  • ·Multi-center evaluation of a novel chemiluminescent rapid assay for the detection of PR3-ANCA

    Página :683-684

    M. Mahler, C. Bentow, A. Vizjak, A. Radice, J. Damoiseaux, M. Miyara, G. Engstler, E. Csernok, M. Fritzler, S. Polanski, J. Wilanska, D. Blockmans, X. Bossuyt

    Resumen Resumen Esquema Esquema
  • ·Comparison of PR3-specific ANCA assays performance for diagnosis of granulomatosis with polyangiitis (GPA)

    Página :684

    A. Radice, L. Bianchi, S. Glionna, B. Trezzi, U. Maggiore, R.A. Sinico

     
  • ·PR3-ANCA: A promising biomarker for the differentiation of ulcerative colitis and Crohn’s disease

    Página :684

    M. Mahler, C. Bentow, D. Blockmans, S. Vermeire, P. Rutgeerts, X. Bossuyt

    
  • ·The association of IgM ANCA with alveolar hemorrhage revisited

    Página :685

    J. Clain, U. Specks, J. Stone

    
  • ·Computer-aided immunofluorescence microscopy (CAIFM) for ANCA diagnostics

    Página :685

    N. Hochstrate, C. Krause, K. Ens, M. Danckwardt, C. Feirer, K. Affeldt, M. Rateike, M. Morrin, D. Wuttig, J. Voigt, K. Fechner, E. Barth, T. Martinetz, W. Stöcker

    
  • ·Patients positive for both MPO-ANCA and PR3-ANCA do not present idiopathic systemic necrotizing vasculitis

    Página :685-686

    A. Chevailler, J.-F. Augusto, J.-F. Subra, D. Lakomy, N.-O. Olsson, A.-S. Denomme, X. Puechal

    Resumen Resumen Esquema Esquema
  • ·Aklides^® – a highly versatile imaging platform for detection of ANCA

    Página :686

    I. Knütter, K. Grossmann, R. Hiemann, D. Reinhold, E. Csernok, D. Roggenbuck

    
  • ·Synergistic effect of GCSF and LPS in ANCA Vasculitis

    Página :686-687

    R. Popat, S. Freeley, M. Robson

    Resumen Resumen Esquema Esquema
  • ·Pathogenic leukocytosis and their susceptibility QTLs for vasculitis and crescentic glomerulonephritis in a model of SCG/Kj mice

    Página :687

    H. Yoshitomo, Y. Wako, M. Naoki, S. Kazuo

    
  • ·Implication of vascular endothelial cell-reactive invariant NKT cells in pathogenesis of small vessel vasculitis in rats

    Página :687

    A. Ishizu, U. Tomaru, C. Iinuma, M. Waki, M. Yamaguchi, A. Kawakami, N. Sasaki, T. Yoshiki

    
  • ·Anti TNF-⍺ drug inhibits initial process of vasculitis in animal model of Kawasaki disease

    Página :687-688

    T. Oharaseki, Y. Yokouchi, H. Yamada, N. Ohno, T. Saji, K. Suzuki, S. Naoe, K. Takahashi

    Resumen Resumen Esquema Esquema
  • ·The role of quantitative trait loci (QTL) in the pathogenesis of experimental autoimmune vasculitis (EAV)

    Página :688

    J.P. Mcdaid, A. Tanna, G. Bhangal, M.A. Little, J. Behmoaras, H.T. Cook, F.W. Tam, A.D. Salama, C.D. Pusey

     
  • ·The protective role of NADPH oxidase in ANCA-induced vasculitis

    Página :688-689

    A. Schreiber, S. Krueger, C. Luft, R. Kettritz

    Resumen Resumen Esquema Esquema
  • ·Investigating Annexin-A1 in ANCA vasculitis and glomerulonephritis

    Página :689

    P. Jukes, F. D’acquisto, R. Pepper, Y. Ghani, M. Perretti, A. Salama, M. Little

     
  • ·Immunization of NOD mice with recombinant mouse proteinase 3 causes immune complex not pauci-immune crescentic glomerulonephritis

    Página :689-690

    P. Hu, H. Xiao, R. Falk, C. Jennette

    Resumen Resumen Esquema Esquema
  • ·Infliximab for Behçet disease with aortic involvement

    Página :690

    M. Okada, M. Kishimoto

    
  • ·Infliximab treatment of resistant uveitis in Behçet disease

    Página :690

    R. Becvar, A. Landova, E. Rihova

    
  • ·Behçet’s disease in children: The Great Ormond Street Hospital experience

    Página :691

    S. Nanthapisal, D. Eleftheriou, Y. Hong, N. Klein, P.A. Brogan

    
  • ·Refractory cutaneous vasculitis associated with MAGIC syndrome: Case report

    Página :691

    M. Mellado, P. Fanlo, E. Bidegain, M. Lopez De Goicoechea, M. Garcia Carasusan, J.M. Arejola

    
  • ·Behçet’s disease and pregnancy

    Página :691-692

    N. Noel, B. Wechsler, J. Nizard, N. Costedoat-Chalumeau, D. Le Thi Huong Boutin, D. Vauthier-Brouzes, M. Dommergues, P. Cacoub, D. Saadoun

    Resumen Resumen Esquema Esquema
  • ·Outcome of neuro-Behçet: Analysis of a large cohort

    Página :692

    N. Noel, B. Wechsler, D. Le Thi Huong Boutin, D. Dormont, P. Cacoub, D. Saadoun

    
  • ·Vessel wall characteristics using high-resolution magnetic resonance imaging in reversible cerebral vasoconstriction syndrome and central nervous system vasculitis

    Página :692

    R. Cerejo, T. Hammad, E. Obusez, S. John, K. Uchino, S. Jones, F. Hui, L. Calabrese, R. Hajj-Ali

    
  • ·Vessel wall characteristics using high-resolution magnetic resonance imaging in reversible cerebral vasoconstriction syndrome and central nervous system vasculitis

    Página :693

    R. Hajj-Ali, R. Cerejo, T. Hammad, E. Obusez, S. John, K. Uchino, S. Jones, F. Hui, L. Calabrese

    
  • ·Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey

    Página :693

    B. Terrier, I. Marie, D. Launay, E. Plaisier, P. Belenotti, J.-E. Kahn, P. Rullier, X. Mariette, P. Cacoub

    
  • ·Characteristics of patients with infectious cryoglobulinemia vasculitis in the absence of HCV infection: Results from the French nationwide CryoVas survey

    Página :694

    B. Terrier, I. Marie, P. Belenotti, F. Bonnet, L. Chiche, A. Hot, J.-E. Kahn, T. Quemeneur, X. Mariette, E. Plaisier, P. Cacoub

    
  • ·Ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis/Peg-IFNa/

    Página :694-695

    D. Saadoun, S. Pol, J.M. Ziza, G. Pialoux, A. Karras, O. Lambotte, P. Cacoub

    Resumen Resumen Esquema Esquema
  • ·Many faces of cutaneous vasculitis in eosinophilic granulomatosis with polyangiitis: An excellent model for histopathology of cutaneous vasculitis

    Página :695

    K.R. Chen

    
  • ·A case of relapse of Churg-Strauss syndrome (CSS) with crescentic lesions

    Página :696

    F. Yoshikazu

    
  • ·Copy number variations of FCGR3B in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

    Página :696

    F. Bonatti, A. Gioffredi, F. Maritati, F. Alberici, M.L. Urban, A. Palmisano, E. Oliva, L. Manenti, B. Tumiati, A. Pesci, P. Fraticelli, G. Guida, G. Moroni, D. Roccatello, G. Gregorini, R.A. Sinico, T.M. Neri, C. Buzio, D. Martorana, A. Vaglio

    
  • ·Methotrexate vs cyclophosphamide as maintenance therapy in severe eosinophilic granulomatosis with polyangitiis (Churg Strauss): A subanalysis of the powercime trial

    Página :696-697

    F. Maritati, M.L. Urban, E. Oliva, F. Alberici, A. Vaglio, C. Buzio

    Resumen Resumen Esquema Esquema
  • ·Clinical assessment of asthma severity partially corresponds to sputum eosinophilic airway inflammation in allergic eosinophilic granulomatosis with polyangiitis

    Página :697

    M. Latorre, C. Baldini, V. Seccia, F. Novelli, S. Bombardieri, P.L. Paggiaro

    
  • ·Clinical value of commonly measured laboratory tests in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

    Página :697-698

    P. Grayson, P. Monach, D. Cuthbertson, S. Carette, G. Hoffman, N. Khalidi, C. Koening, C. Langford, K. Mckinnon-Maksimowicz, C. Pagnoux, P. Seo, U. Specks, S. Ytterberg, P. Merkel

    Resumen Resumen Esquema Esquema
  • ·A multicenter survey of rituximab for eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

    Página :698

    A. Hot, M.J. Guerry, R. Smith, P. Sivasothy, L. Guillevin, P. Merkel, D. Jayne

    
  • ·Limited otological eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) – a new disease subset

    Página :699

    J. Der Kureghian, N. Donnelly, P. Axon, P. Jani, D. Jayne

    
  • ·The ear, nose and throat manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

    Página :699

    J. Der Kureghian, P. Jani, D. Jayne

    
  • ·ANCA-positive and ANCA-negative phenotypes of eosinophilic granulamatosis and polyangiitis (EGPA): Outcome and long-term follow-up of 46 patients from a single Polish centre

    Página :699-700

    W. Szczeklik, B. Sokolowska, P. Kuczia, J. Gasior, M. Maga, S. Bartyzel, J. Musial

    Resumen Resumen Esquema Esquema  
  • ·A scoring tool for ear, nose and throat disease activity and damage in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

    Página :700

    J. Der Kureghian, P. Jani, D. Jayne

     
  • ·Serum biomarkers during relapsing disease in eosinophilic granulomatosis with polyangiitis

    Página :700-701

    C. Dejaco, P. Monach, D. Cuthbertson, S. Carette, G. Hoffman, N. Khalidi, C. Koening, C. Langford, K. Mckinnon-Maksimowicz, P. Seo, U. Specks, S. Ytterberg, P. Merkel, J. Zwerina

    Resumen Resumen Esquema Esquema
  • ·Eosinophilic granulomatosis with polyangitis (EGPA): Clinical and immunologic expression in a single center cohort

    Página :701

    C. Baldini, M. Latorre, V. Seccia, A. Della Rossa, A. Tavoni, P.L. Paggiaro, S. Sellari Franceschini, S. Bombardieri

    
  • ·Sinonasal involvement in patients with eosinophilic granulomatosis with polyangitis (EGPA, ex Churg Strauss Syndrome): A modern look to an ancient problem

    Página :701

    V. Seccia, C. Baldini, M. Latorre, S. Fortunato, L. Cristofani-Mencacci, P.L. Paggiaro, S. Sellari-Franceschini, S. Bombardieri

    
  • ·A case of eosinophilic granulomatosis with polyangiitis (EGPA) who relapsed with saddle nose

    Página :701-702

    M. Saito, Y. Komagata, T. Takahashi, A. Isomura, S. Kawashima, K. Fukuoka, M. Karube, K. Yoshihara, S. Kaname, Y. Arimura, A. Yamada

    Resumen Resumen Esquema Esquema
  • ·Referral causes and initial diagnosis of ANCA-associated vasculitides in a pulmonary tertiary centre. Retrospective study in 90 patients

    Página :702

    L.F. Flores-Suárez, M. Alba

    
  • ·ANCA in Auckland 1998–2008

    Página :702-703

    J. De Zoysa, J. Kendrick Jones, M. Lam, M. Yehia

    Resumen Resumen Esquema Esquema
  • ·Microscopic polyangiitis in the setting of usual interstitial pneumonia

    Página :703

    K. Keogh, M. Baqir, U. Specks, G. Aughenbaugh, G. Battaglia, F. Londrino, A. Tironi, S. Monti, G. Gina

    
  • ·Incidence of granulomatosis with polyangiitis (Wegener’s) among Greenlanders

    Página :703

    M. Faurschou, M. Helleberg, N. Obel, B. Baslund

    
  • ·ANCA-associated vasculitides (AAV) from the gender point of view

    Página :703-704

    A. Radice, L. Bianchi, S. Glionna, B. Trezzi, R.A. Sinico

    Resumen Resumen Esquema Esquema
  • ·Anti-neutrophil cytoplasmic antibodies associated vasculitis frequency in Dr. Manuel Quintela university hospital

    Página :704

    N. Rodriguez Sisniega, E. Araujo, C. Buzzi, N. Garcia, P. Lopez, C. Montenegro, R. Balleste, L. Borche

    
  • ·Epidemiologic study of primary systemic vasculitides in adults in Southeastern Spain (Costa del Sol Occidental region, Málaga)

    Página :705

    C. Romero-Gómez, J.A. Aguilar-García, M.D. García De Lucas, R. Cotos-Canca, J.J. García-Alegría, J. Hernández-Rodríguez

    
  • ·Pattern of renal involvement and its correlation with outcomes in patients with small and medium vessel vasculitis – experience from a tertiary care center in India

    Página :705-706

    A. Sharma, T. Mittal, M. Rathi, R. Nada, R. Rajan, R. Minz, K. Joshi, S. Singh, V. Sakhuja

    Resumen Resumen Esquema Esquema
  • ·Pandemic influenza vaccine in granulomatosis with polyangiitis: Adequate humoral response and safety in inactive patients

    Página :706

    N.E. Aikawa, A.L. Calich, S.K. Shinjo, A.C. Medeiros, M. Levy-Neto, V.S. Viana, J.C. Moraes, M.D.C. Timenetsky, E. Bonfa, R.M. Pereira

    
  • ·The association of granulomatosis with polyangiitis and IgG4-related disease: A case series

    Página :706-707

    L. Dudley, L. Brown, J. Pettus, C. Black, N. Orzechowski

    Resumen Resumen Esquema Esquema
  • ·Multiple infections in a Filipino with polyangiitis overlap syndrome (POS)

    Página :707

    G. Racaza, L. Abrahan Iv, K.A. Reyes, E. Penserga

    
  • ·Cardiovascular risk in different variants of granulomatosis with polyangiitis (Wegener’s)

    Página :707-708

    E. Kuznetsova, S. Moiseev, P. Novikov

    Resumen Resumen Esquema Esquema
  • ·Long-term follow-up of 96 GPA patients at a single centre

    Página :708

    F. Rees, M. Al-Deiri, P. Lanyon

    
  • ·Analysis of whole-blood micro-rna profiles in PR-3-ANCA positive vasculitis

    Página :708

    T. Kirsch, A. Bertram, S. Lovric, J.K. Park, J. Becker, M. Haubitz

    
  • ·Successful pregnancy in patients with granulomatosis with polyangiitis (Wegener’s) after rituximab treatment

    Página :709

    P. Novikov, E. Kuznetsova, O. Borodin, A. Meshkov, S. Moiseev

    
  • ·Distinct eicosanoid profile in exhaled breath condensates from granulomatosis with polyangiitis (Wegener’s) patients

    Página :709

    W. Szczeklik, M. Sanak, J. Sznajd, B. Jakieła, B. Sokołowska, M. Kaszuba, A. Sawina, J. Musial

     
  • ·Alveolar hemorrhage, rectus muscle hematoma, and gastrointestinal bleeding accompanied by crescentic glomerulonephritis in a patient with PR3-ANCA disease

    Página :709-710

    Y. Cao

    Resumen Resumen Esquema Esquema  
  • ·Characterization of F-18 fluorodeoxyglucose PET/CT in granulomatosis with polyangiitis

    Página :710

    D. Nelson, G. Johnson, R. Cartin-Ceba, U. Specks

    
  • ·Presentation and management of granulomatosis with polyangiitis (Wegener’s) (GPA) central nervous system (CNS) involvement

    Página :710

    G. De Luna, B. Terrier, P. Charles, C. Pagnoux, X. Puechal, P. Cohen, L. Mouthon, L. Guillevin

    
  • ·Pituitary dysfunction in granulomatosis with polyangiitis

    Página :710-711

    R. Cartin-Ceba, E. Singh, T. Peikert, K. Keogh, D. Erickson, U. Specks

    Resumen Resumen Esquema Esquema
  • ·Inter-observer reproducibility of two CT scan staging systems to evaluate sinonasal involvement in granulomatosis with polyangiitis (Wegener’s)

    Página :711

    P. Díaz, G. Faba, D. Contreras, R. Zunino, C. Ortega, F. Silva

    
  • ·Pathogenesis of atherosclerosis in granulomatosis with polyangiitis

    Página :711

    R. Hajj-Ali, G. Hoffman, R. Silverstein, T. Clark, C. Langford

    
  • ·Maintenance treatment in childhood granulomatosis with polyangiitis

    Página :712

    M. Twilt, R. Schneider, D. Hebert, E. Harvey, R. Laxer, S. Dell, C. Licht, S. Benseler

    
  • ·GPA and MPA patients have different serum cytokine profiles

    Página :712

    A. Avik, Y. Sundström, L. Berg, A. Bruchfeld, V. Malmström, I. Gunnarsson

    
  • ·A case of lung biopsy-proven MPO-ANCA positive granulomatosis with polyangiitis (GPA; Wegener’s granulomatosis)

    Página :712-713

    K. Murakami, M. Saito, Y. Komagata, K. Yoshihara, S. Kaname, Y. Arimura, A. Yamada, Y. Nakamoto, M. Ishida, M. Hikgaki, H. Takizawa, R. Kawauchi, T. Goya, M. Fujiwara, T. Yazawa, H. Kamma

    Resumen Resumen Esquema Esquema
  • ·Interleukin 15, CD56+ T-cells and ANCA-associated vasculitis (AAV)

    Página :713

    B.M. Buhl, C. Stegeman, C.G.M. Kallenberg, A. Rutgers, W.H. Abdulahad

    
  • ·Resolution of proteinuria and hematuria in ANCA-associated nephritis

    Página :713

    S. Lilliebladh, A. Mohammad, K. Westman, M. Segelmark

    
  • ·Central nervous system involvement in granulomatous polyangiitis (GPA)

    Página :714

    O. Karadag, O. Helvaci, I. Dogan, U. Kalyoncu, A. Akdogan, L. Kilic, S. Kiraz

    
  • ·Clinical manifestations of granulomatosis with polyangiitis (Wegener’s granulomatosis) in the upper respiratory tracts

    Página :714

    O. Iaremenko, L. Petelytska

    
  • ·Immunopathology of active and remitting granulomatosis with poyangiitis (Wegener’s)

    Página :714-715

    L. Rani, R. Minz, A. Sharma, S. Anand, D. Gupta, N. Panda, V. Sakhuja

    Resumen Resumen Esquema Esquema
  • ·Tracheobronchial stenoses (TBS) in granulomatosis with polyangiitis (Wegener) (GPA)

    Página :715

    C. Girard, V. Cottin, J.-F. Cordier, L. Guillevin

    
  • ·Wegener or Churg Strauss

    Página :715

    S. Saliba

    
  • ·Predicting relapse in granulomatosis with polyangiitis: The role of biomarkers

    Página :716

    P. Hogan, R. O’connell, E. Browne, S. Scollard, E. Hackett, C. Feighery

    
  • ·Circulating gamma delta T cells are significantly reduced in granulomatosis with polyangiitis

    Página :716

    S. Scollard, B. Mangan, D. Doherty, N. Conlon, C. Feighery

    
  • ·Proteinase 3 reactive T cells in patients with granulomatosis with polyangiitis

    Página :716

    S. Scollard, R. Comerford, N. Conlon, C. Feighery

    
  • ·Vitamin D level is decreased in patients with Takayasu’s arteritis

    Página :716-717

    F. Alibaz-Oner, O. Asmaz Haliloglu, D. Gogas Yavuz, M. Can, H. Direskeneli

    Resumen Resumen Esquema Esquema
  • ·Presence of fibromyalgia and fatigue is not increased in patients with Takayasu’s arteritis

    Página :717

    F. Alibaz-Oner, M. Can, B. Ilhan, O. Polat, H. Direskeneli

    
  • ·Impaired endothelial function in patients with Takayasu’s arteritis

    Página :717-718

    F. Alibaz-Oner, S. Yurdakul, S. Aytekin, H. Direskeneli

    Resumen Resumen Esquema Esquema
  • ·Impairment in aortic elastic properties and mechanics of carotid artery system in patients with Takayasu’s arteritis

    Página :718

    F. Alibaz-Oner, S. Yurdakul, S. Aytekin, H. Direskeneli

    
  • ·The higher response of pandemic influenza vaccination in Takayasu’arteritis: A prospectively controlled study

    Página :718-719

    A.L. Calich, S.T. Shinjo, A.C. Ribeiro, N.E. Aikawa, M. Levy-Neto, C.G. Saad, A.R. Precioso, M.D.C. Timenetsky, E. Bonfa, R.M. Pereira

    Resumen Resumen Esquema Esquema
  • ·Takayasu’s arteritis in southern Sweden

    Página :719

    A. Mohammad, T. Mandl

    
  • ·ITAS.A suggests persistent disease activity in Takayasu aorto-arteritis after 6 months induction therapy

    Página :719

    P. Bacon

    
  • ·Outcome of vascular interventions in Takayasu arteritis

    Página :720

    M. Rajappa

    
  • ·14-3-3 in large vessel vasculitis: A novel antigen

    Página :720

    R. Chakravarti, K. Gupta, L. Svensson, E. Roselli, G. Pettersson, D. Johnston, E. Soltesz, T. Daly, D. Stuehr, G. Hoffman

    
  • ·Methotrexate plus prednisone in patients with relapsing chronic periaortitis

    Página :720-721

    F. Alberici, A. Palmisano, M.-L. Urban, F. Maritati, E. Oliva, L. Manenti, S. Ferretti, R. Cobelli, C. Buzio, A. Vaglio

    Resumen Resumen Esquema Esquema  
  • ·Outcome of 1516 percutaneous interventions in 401 patients with Takayasu arteritis – a single-center experience from South India

    Página :721

    G. Joseph, D. Danda

    
  • ·Aortic dissection in giant cell arteritis: A population-based study of predictors

    Página :721-722

    T. Kermani, K. Warrington, C. Crowson, G. Hunder, S. Ytterberg, S. Gabriel, E. Matteson

    Resumen Resumen Esquema Esquema
  • ·Patients with Takayasu’s arteritis having persistent acute phase response usually have an increased major vessel uptake by 18F-FDG-PET

    Página :722

    F. Alibaz-Oner, F. Dede, T. Ones, H.T. Turoglu, H. Direskeneli

    
  • ·Can serum procalcitonin help to diagnose patients with new onset giant cell arteritis?

    Página :722

    A.P. Diamantopoulos, H. Hetland, G. Myklebust, D.M. Soldal, G. Haugeberg

    
  • ·Large vessel giant cell arteritis: Clinical, imaging characteristics and outcomes

    Página :722-723

    T. Kermani, F. Muratore, C. Crowson, A. Green, E. Matteson, K. Warrington

    Resumen Resumen Esquema Esquema
  • ·Efficacy of long-term treatment with TNF inhibitors in patients with refractory Takayasu arteritis

    Página :723

    P. Novikov, I. Smitienko, S. Moiseev

    
  • ·Serum osteopontin in giant cell arteritis: A biomarker associated with sistemic inflammatory response and relapsing course

    Página :723

    S. Prieto-González, M. Corbera-Bellalta, E. Planas-Rigol, A. García-Martínez, M.A. Alba, I. Tavera-Bahillo, G. Espígol-Frigolé, J. Hernández-Rodríguez, M.C. Cid

    
  • ·ANCA-associated systemic vasculitis is associated with impaired dilatory capacity of the conduit brachial artery – a link to increased cardiovascular risk?

    Página :723-724

    P. Clausen, W. Szpirt, B. Feldt-Rasmussen

    Resumen Resumen Esquema Esquema
  • ·Normal frequencies of circulating Th1 and Th17 cells in GCA patients

    Página :724

    K. Van Der Geest, W. Abdulahad, G. Horst, A. Rutgers, E. Brouwer, A. Boots

    
  • ·Initial presentation of giant cell arteritis with ischemic optic neuropathy without headache: Report of four cases

    Página :724

    V. Duro, C. Perez, P. Fanlo, I. Elejalde, M. Etxebarria, M. Gonzalez

    
  • ·Rapid control of disease activity by Tocilizumab in ten “difficult-to-treat” cases of Takayasu arteritis

    Página :725

    R. Goel, D. Danda, S. Kumar, G. Joseph

    
  • ·Chronic periaortitis and autoimmune thyroiditis: A novel association

    Página :725

    M.L. Urban, G. Ceresini, A. Palmisano, D. Corradi, E. Usberti, C. Buzio, A. Vaglio

    
  • ·Tocilizumab in refractory Takayasu arteritis: Case series and literature review

    Página :725-726

    N. Abisror, A. Mekinian, C. Lavigne, M.-A. Vandenehende, M. Soussan, O. Fain

    Resumen Resumen Esquema Esquema  
  • ·Study of side effects of glucocorticoid treatment in 28 patients with giant cell arteritis (GCA)

    Página :726

    E. Huarte, P. Fanlo, B. Lacruz, U. Gutierrez, F. García Bragado, F. Jimenez, R. Arnáez

    
  • ·Leflunomide as a corticosteroid-sparing agent in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR): A consecutive case series

    Página :726-727

    H. Hetland, G. Myklebust, A.P. Diamantopoulos

    Resumen Resumen Esquema Esquema
  • ·Tocilizumab for the treatment of giant cell arteritis: Extended follow-up

    Página :727

    S. Unizony, B. Keroack, J.H. Stone

    
  • ·Severe relapse of Takaysu arteritis on ongoing treatment with tocilizumab

    Página :727

    R. Gunnarsson, Ø. Midtvedt, Ø. Palm, E. Merckoll, K. Johnsrud

    
  • ·Asymptomatic myocardial ischemic disease in Takayasu’s arteritis: Detection by magnetic resonance imaging

    Página :728

    C. Comarmod, P. Cluzel, N. Costedoat-Chalumeau, R. Isnard, F. Koskas, P. Cacoub, D. Saadoun

    
  • ·Systemic large vessel vasculitis pattern in chronic periaortitis: Identification of a new disease subset

    Página :728

    A. Palmisano, M.L. Urban, F. Alberici, F. Maritati, C. Salvarani, C. Buzio, A. Vaglio

    
  • ·A single centre experience of 40 children with Takayasu arteritis from India

    Página :728-729

    R. Goel, D. Danda, S. Kumar, G. Joseph

    Resumen Resumen Esquema Esquema  
  • ·IgG4 in chronic periaortitis

    Página :729

    E. Oliva, F. Maritati, A. Palmisano, F. Alberici, C. Buzio, A. Vaglio

    
  • ·Takayasu arteritis (TA) and sacroiliitis. A large vessels vasculitis masquerade from anti-TNF alpha therapy

    Página :729

    P. Toniati, A. Tincani

    
  • ·ITAS.A suggests persistent disease activity in Takayasu aorto-arteritis (TA) after induction therapy

    Página :729-730

    R. Misra, D.P. Misra, D. Danda, A. Lawrence, P.A. Bacon

    Resumen Resumen Esquema Esquema
  • ·Chronic asymptomatic aortic dissection (AD) in Takayasu’s arteritis (TA); how to treat?

    Página :730

    S.T. Tosounidou, D.C. Carruthers

    
  • ·Contribution of anti-ferritin antibodies to the diagnosis of giant cell arteritis

    Página :730-731

    A. Regent, K.H. Ly, A. Blet, C. Agard, X. Puéchal, N. Tamas, C. Le-Jeunne, E. Vidal, L. Guillevin, L. Mouthon

    Resumen Resumen Esquema Esquema
  • ·Increased migration and proliferation potential characterized vascular smooth muscle cells from patients with giant cell arteritis

    Página :731

    A. Regent, K. Ly, G. Clary, C. Philippe, B. Cédric, C. Le-Jeunne, E. Vidal, A. Brezin, V. Witko-Sarsat, L. Guillevin, L. Mouthon

    
  • ·Takayasu arteritis in Tunisia: Clinical study of 34 cases

    Página :731

    I. Ben Ghorbel, N. Belfeki, S. Souissi, A. Hamzaoui, T. Ben Salem, M. Khanfir, M. Lamloum, M. Miled, H. Houman

    
  • ·Radiological features in Takayasu’ arteritis in Tunisia. About 34 cases

    Página :731-732

    N. Belfeki, I. Ben Ghorbel, S. Souissi, A. Hamzaoui, T. Ben Salem, M. Khanfir, M. Lamloum, M. Miled, H. Houman

    Resumen Resumen Esquema Esquema
  • ·Long-term outcome of 123 microscopic polyangiitis patients in a monocentric German cohort

    Página :732

    S. Schinke, E. Reinhold-Keller, M. Both, B. Nölle, M. Laudien, W. Gross, J. Holle

    
  • ·The role of MPO-positive cells and MPO deposition in glomerular capillary injury in patients with various glomerulonephritis

    Página :732-733

    S. Kawashima, Y. Arimura, Y. Komagata, S. Kaname, A. Yamada

    Resumen Resumen Esquema Esquema
  • ·Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan

    Página :733

    S. Furuta, A. Chaudhry, Y. Hamano, S. Fujimoto, H. Nagafuchi, S. Ozaki, H. Makino, S. Matsuo, T. Endo, E. Muso, C. Ito, E. Kusano, M. Yamagata, K. Ikeda, D. Kasiwakuma, I. Iwamoto, K. Westman, D. Jayne

    
  • ·Prediction of outcome of treatment by gene expression profiling of peripheral blood in patients with microscopic polyangiitis

    Página :733

    A. Ishizu, U. Tomaru, T. Murai, T. Yamamoto, T. Atsumi, T. Yoshiki, H. Makino, S. Ozaki

    
  • ·Serum C-reactive protein reflects the proportions of cellular crescent formation and glomerulosclerosis in patients with microscopic polyangiitis

    Página :734

    T. Iwakiri, Y. Matsuura, A. Yamashita, S. Uezono, S. Hisanaga, T. Tokura, K. Kitamura, Y. Asada, S. Fujimoto

    
  • ·Unilateral vocal cord paralysis as initial manifestation of severe microscopic polyangiitis (MPA)

    Página :734

    L.F. Flores-Suárez, G. Tona

    
  • ·Rapidly progressive glomerulonephritis is not the sole presentation of renal involvement in ANCA associated vasculitis

    Página :734-735

    C. Levi, E. Thervet, E. Guiard, L. Mouthon, C. Daniliuc, M. Roland, L. Guillevin, D. Nochy, C. Jacquot, A. Karras

    Resumen Resumen Esquema Esquema
  • ·Abnormal glycosylation of serum IgG from patients with ANCA-associated systemic vasculitis: Relation to disease activity

    Página :735

    O. Lardinois, J. Hess, L. Deterding, L. Aybar, S. Hogan, J. Mcgregor, C. Poulton, Y. Hu, C. Henderson, D. Bunch, R. Falk

    
  • ·Renal histopathological classification of ANCA associated glomerulonephritis: A validation study of 92 patients

    Página :735-736

    E. De Sousa Amorim, A. Ros Abando, A. Casian, D. Jayne

    Resumen Resumen Esquema Esquema  
  • ·Aortitis evidenced by PET-CT 18FDG in the setting of ANCA-associated vasculitis: About four cases

    Página :736

    T. Nguyen, E. Cogan, D. Blocklet, F. Vandergheynst

     
  • ·The informational needs of patients with ANCA-vasculitis – a multinational study

    Página :736-737

    J. Mooney, P.A. Merkel, F. Poland, N. Spalding, D. Sheriff, P. Grayson, R. Richesson, R. Le Duc, D.G.I. Scott, R.A. Watts

    Resumen Resumen Esquema Esquema
  • ·Proposal of an algorithm for the diagnosis and aetiologic identification of diffuse alveolar haemorrhage (DAH)

    Página :737

    C. Ramírez-Assad, F. Contreras-Rodríguez, J. Cedillo, E. Bautista, L.F. Flores-Suárez

     
  • ·Validation of the Birmingham Vasculitis activity score (BVAS) and the Vasculitis Damage Index (VDI) in a population of patients with ANCA-associated vasculitis (AASV) in Mexico

    Página :737

    C. Ramírez-Assad, M.H. Cardiel, L.F. Flores-Suárez

    
  • ·Illness perceptions and fatigue in systemic vasculitis

    Página :737-738

    P. Grayson, N. Amudala, C. Mcalear, R. Leduc, D. Shereff, R. Richesson, L. Fraenkel, P. Merkel

    Resumen Resumen Esquema Esquema
  • ·Successful treatment with rituximab in patients with Schnitzler syndrome

    Página :738

    P. Novikov, E. Kuznetsova, V. Pulina, A. Meshkov, N. Nikiforova

    
  • ·Rituximab and vascular function in granulomatosis with polyangiitis (GPA)

    Página :738-739

    A. Casian, K. Maki-Petaja, J. Cheriyan, A. Hubsch, I. Wilkinson, D. Jayne

    Resumen Resumen Esquema Esquema  
  • ·Serial chest high-resolution CT (HRCT) scans in patients with ANCA-associated vasculitis

    Página :739

    P. Konopasek, D. Altmanova, Z. Hruskova, E. Jancova, B. Svobodova, V. Tesar

    
  • ·Association between thyroid disease and ANCA associated vasculitis

    Página :739-740

    M. Prendecki, A. Tanna, E. Clutterbuck, C. Pusey

    Resumen Resumen Esquema Esquema
  • ·Single-organ gallbladder vasculitis: Characterization and distinction from systemic vasculitis involving the gallbladder. An analysis of 57 patients

    Página :740

    J. Hernández-Rodríguez, C.D. Tan, E.R. Rodríguez, G.S. Hoffman

    
  • ·Weight loss – a common presentation in a rare disease. IgG4 related disease (IgG4 RD) is an emerging diagnosis not to miss

    Página :740-741

    S.T. Tosounidou, D.C. Carruthers

    Resumen Resumen Esquema Esquema
  • ·Silica binds to LL-37 and CpG DNA complexes

    Página :741

    P.R. Hurtado, J. Nitschke, E. Hurtado-Perez, C.A. Peh

    
  • ·Aneurysms in the view of rheumatology perspective

    Página :741

    O. Karadag, U. Kalyoncu, L. Kilic, E. Er, A.G. Er, I. Dogan, A. Akdogan, I. Ertenli

    
  • ·IgA associated vasculitis (IgAV) – a 5-year retrospective study

    Página :741-742

    C. Gota, S. Billings, C. Langford

    Resumen Resumen Esquema Esquema
  • ·Macrophage activation syndrome in vasculitis: An underrecognised complication?

    Página :742

    L. Damian, C. Cismaru, L. Ghib, M. Muresan, B. Stancu, M. Sfichi, I. Felea, I. Filipescu, S. Rednic, A. Bojan

    
  • ·Retroperitoneal fibrosis at the onset of ANCA associated vasculitis: The risk of a delay in the diagnosis of vasculitis

    Página :742

    S. Possenti, F. Londrino, G. Jeannin, C. Salviani, G. Cancarini, G.A. Gregorini

    
  • ·Positron emission tomography scanning in ANCA associated vasculitis

    Página :742

    M. Kemna, S. Vöö, P. Van Paassen, S. Timmermans, M. Van Kroonenburgh, J.W. Cohen Tervaert

    
  • ·Circulating microRNAs in ANCA vasculitis correlate to renal function, hemoglobin and risk of relapse

    Página :743

    C. Skoglund, A.L. Carlsen, M. Weiner, T. Kurz, T. Hellmark, P. Eriksson, N. Heegaard, M. Segelmark

    
  • ·Hemorrhagic emergency due to intrahepatic aneurism rupture in a patient with Polyateritis Nodosa after long time of episodic fever: A case report

    Página :743-744

    F. Silva, M. Cisternas, G. Maguida, M.I. Ruiz, P. Diaz, S. Gonzalez, J. Martinez, L. Meneses, L. Massardo

    Resumen Resumen Esquema Esquema
  • ·Clinical characteristics of ANCA associated vasculitis in hispanic patients: Single centre experience in Chile

    Página :744

    M. Cisternas, M.J. Lira, F. Silva

    
  • ·Long-term outcomes of patients with Reversible Cerebral Vasoconstriction Syndrome (RCVS)

    Página :744

    S. John, L. Calabrese, K. Uchino, S. Tepper, M. Stillman, R. Hajj-Ali

    
  • ·Treatment related damage in the ANCA-associated vasculitides: An analysis of cohorts from the European Vasculitis Study Group (EUVAS) therapeutic trials

    Página :744-745

    J. Robson, H. Doll, O. Flossmann, S. Ravi, H. Lorraine, H. Peter, J. David, M. Chetan, W. Kerstin, L. Raashid

    Resumen Resumen Esquema Esquema  
  • ·Factors associated with long-term damage in the ANCA-associated vasculitides: An analysis of cohorts from the European vasculitis study group (EUVAS) therapeutic trials

    Página :745

    J. Robson, H. Doll, F. Oliver, S. Ravi, H. Lorraine, H. Peter, J. David, M. Chetan, W. Kerstin, L. Raashid

    
  • ·Markers for work disability in ANCA-associated vasculitis

    Página :745-746

    N. Basu, A. Mcclean, L. Harper, M. Little, R. Luqmani, O. Flossmann, D. Jayne, N. Dhaun, V. Kumar, J. Mclaren, E. Amft, L. Erwig, G. Macfarlane, D. Reid, G. Jones

    Resumen Resumen Esquema Esquema
  • ·Long-term outcome of GPA and MPA in a population based cohort

    Página :746

    R.A. Watts, J. Mooney, C. Mukhtyar, C. Sheehy, D.G.I. Scott

    
  • ·ADAPTIV: A Delphi study to assess morbidity prevention and treatment in vasculitis

    Página :746-747

    N. Brown, D. Tooth, A. Summers, M. Venning

    Resumen Resumen Esquema Esquema
  • ·Estimating renal survival using the ANCA-associated glomerulonephritis classification: A validation study

    Página :747-748

    B. Wilde, P. Van Paassen, P. Van Breda Vriesman, J.W. Cohen Tervaert, M. Hilhorst

    Resumen Resumen Esquema Esquema  
  • ·Towards an international standardized ENT disease activity score in GPA

    Página :748

    M. Martinez Del Pero, M. Laudien, N. Rasmussen

    
  • ·Cardiovascular outcomes and prognostic predictors in ANCA-associated vasculitis

    Página :748-749

    C. Yuste, A. Casian, C. Jironda, D. Jayne

    Resumen Resumen Esquema Esquema
  • ·The value of a patient global assessment for disease activity in granulomatosis with polyangiitis

    Página :749

    G. Tomasson, J.C. Davis, G.S. Hoffman, W.J. Mccune, U. Specks, R. Spiera, E.W. St. Clair, J.H. Stone, P.A. Merkel

    
  • ·Patient reported outcomes in ANCA-associated vasculitis. A prospective comparison between BVAS and RAPID3 on an MDHAQ

    Página :749

    O. Elsallabi, J. Block

    
  • ·Severe fatigue and psychological morbidity in ANCA-associated vasculitis

    Página :749-750

    A. Mcclean, N. Basu, D. Jones, M. Morgan, J. Bosch, L. Harper

    Resumen Resumen Esquema Esquema
  • ·Severe fatigue in ANCA-associated vasculitis is associated with altered perception and reduced cardiovascular fitness

    Página :750

    A. Mcclean, N. Basu, D. Jones, M. Morgan, J. Bosch, L. Harper

    
  • ·Predicting renal relapse with the histopathologic classification of ANCA-associated glomerulonephritis

    Página :750-751

    A. Göçeroğlu, R.A.F. De Lind Van Wijngaarden, A.E. Berden, K. Westman, O. Flossmann, M. Walsh, M. Fiocco, R. Wolterbeek, H.A. Hauer, D. Jayne, G. Gaskin, N. Rasmussen, L.H. Noël, F. Ferrario, R. Waldherr, C. Pusey, E.C. Hagen, J.A. Bruijn, I.M. Bajema

    Resumen Resumen Esquema Esquema
  • ·Antineuthropil cytoplasmic autoantibody-associated vasculitis (AAV) in older patients (REVAS Study)

    Página :751

    R. Solans, L. Caminal, G. Fraile, L. Saez, J.J. Rios, M. Monica, X. Xavier, M. Monica, C.M. Jesus

    
  • ·ANCA vasculitis and atypical hemolytic uremic syndrome: An association with poor outcome

    Página :752

    E. Gnappi, L. Signorini, A. Vaglio, F. Pilato, L. Manenti

     
  • ·Long-term outcome of severe alveolar hemorrhage in ANCA-associated vasculitis: A retrospective cohort study

    Página :752

    Z. Hruskova, A. Casian, P. Konopasek, B. Svobodova, D. Frausova, V. Lanska, V. Tesar, D. Jayne

    
  • ·Acute respiratory distress syndrome (ARDS) as primary manifestation in ANCA-associated vasculitis

    Página :752-753

    M. Dolch, M. Irlbeck, M. Wessely, S. Rau, L. Frey, U. Schönermarck

    Resumen Resumen Esquema Esquema
  • ·Focal necrotizing and crescentic glomerulonephritis in patients with normal serum creatinine

    Página :753

    S.P. Mcadoo, A. Tanna, O. Randone, M. Griffith, J. Levy, T. Cook, T. Cairns, C. Pusey

    
  • ·Clinical and pathological study on 34 patients with primary ANCA-associated systemic vasculitis with renal immune complex deposition

    Página :753

    X. Li, W. Zhang, X. Pan, N. Chen

    
  • ·Long-term outcome of low dose cyclophosphamide (CYC) and plasma exchange (PLEX) induction in ANCA-associated vasculitis (AAV)

    Página :754

    W. Szpirt, E. Krarup, M. Egfjord

    
  • ·Longitudinal ANCA measurements for predicting a relapse are useful in patients with severe disease but not in patients with limited disease

    Página :754

    M. Kemna, J. Damoiseaux, J. Austen, B. Winkens, J. Peters, P. Van Paassen, J.W. Cohen Tervaert

    
  • ·Low %CD5+ B cells in patients with ANCA vasculitis portends a shorter time to relapse after rituximab

    Página :754-755

    D. Bunch, J. Mcgregor, L. Aybar, E. Studstill, Y. Hu, S. Hogan, K. Colby, C. Poulton, C. Mendoza, J. Schmitz, R. Falk, P. Nachman

    Resumen Resumen Esquema Esquema
  • ·Monocyte chemoattractant protein-1 (MCP-1) in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis: Biomarker potential and association with polymorphisms in the MCP-1 and the CC chemokine receptor-2 (CCR2) gene

    Página :755

    N. Jönsson, L. Gunnarsson, A. Pettersson, S. Ohlsson

    
  • ·Abundant neutrophil extracellular traps in thrombus of patient with microscopic polyangiitis

    Página :755

    D. Nakazawa, U. Tomaru, S. Jodo, S. Nishio, T. Atsumi, A. Ishizu

    
  • ·Characterization of regulatory B cells in ANCA-associated vasculitis (AAV)

    Página :755-756

    N. Lepse, W.H. Abdulahad, A. Rutgers, C.A. Stegeman, C.G. Kallenberg, P. Heeringa

    Resumen Resumen Esquema Esquema
  • ·Epitope analysis of anti-myeloperoxidase antibodies in patients with ANCA-associated vasculitis

    Página :756

    S.J. Gou, P.C. Xu, M. Chen, M.H. Zhao

    
  • ·Investigating the microRNA signature of ANCA associated vasculitis

    Página :756-757

    N. Brown, S. Harris, M. Venning, P. Brenchley

    Resumen Resumen Esquema Esquema
  • ·The interaction between C5a and sphingosine-1-phosphate in neutrophils for ANCA-mediated activation

    Página :757

    J. Hao, C. Wang, M. Chen, M.H. Zhao

    
  • ·Circulating level of high mobility group box-1 is associated with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis

    Página :757-758

    C. Wang, M. Chen

    Resumen Resumen Esquema Esquema
  • ·Pentraxin-3 and soluble tumor necrosis factor-like weak inducer of apoptosis (s-Tweak) in anti-neutrophil antibody associated vasculitis (AAV)

    Página :758

    M. Wendt, O. Borjesson, A. Avik, J. Bratt, A.R. Qureshi, I. Gunnarsson, A. Bruchfeld

    
  • ·Epitope analysis of anti-myeloperoxidase antibodies in propylthiouracil-induced ANCA-associated vasculitis

    Página :758

    C. Wang, M. Chen

    
  • ·IL-10 producing regulatory B-cells are diminished in ANCA-associated vasculitis

    Página :758-759

    B. Wilde, M. Thewissen, P. Van Paassen, M. Hilhorst, J. Damoiseaux, O. Witzke, J.W. Cohen Tervaert

    Resumen Resumen Esquema Esquema
  • ·Interleukin-21, B cell activating factor and unmethylated CpG oligodeoxynucleotides synergize in promoting anti-Proteinase 3 autoantibody production in vitro

    Página :759

    N. Lepse, J. Land, A. Rutgers, C.G. Kallenberg, C.A. Stegeman, W.H. Abdulahad, P. Heeringa

    
  • ·DNA from neutrophil extracellular traps is hypomethylated

    Página :759

    E. Hurtado, J. Nitschke, P. Hurtado, C.A. Peh

    
  • ·ANCA reactive B cells and neutrophils cross-talk in the pathogenesis of AAV: A model proposal

    Página :760

    P.R. Hurtado, J. Nitschke, E. Hurtado-Perez, C.A. Peh

    
  • ·Tissue destruction in granulomatosis with polyangiitis: Common histological pattern in mice and men

    Página :760

    N. Kesel, U. Schumacher, M. Laudien, K. Holl-Ulrich, W. Gross, A. Müller, S. Ullrich

    
  • ·Coagulation activity in renal ANCA-positive vasculitis

    Página :760-761

    A.E. Ekstrand, R.L. Lassila, L.J.K. Joutsi-Korhonen, A.S. Salmela

    Resumen Resumen Esquema Esquema
  • ·Galactosylation and sialylation of anti-proteinase 3 antibodies in granulomatosis with polyangiitis is associated with increased inflammatory cytokines

    Página :761

    M. Morgan, K. Stavenhagen, C. Koeleman, A. Hipgrave-Ederveen, L. Harper, B. Jacobs, C. Savage, R. Jefferis, A. Deelder, M. Wuhrer

    
  • ·LAMP-2, a potential novel receptor on human monocytes derived dendritic cells (MDDC)

    Página :761-762

    D.L. Leone

    Resumen Resumen Esquema Esquema
  • ·Autoantibodies for several antigens in neutrophil cytoplasm other than PR3 and MPO also promote release of NETs from neutrophils

    Página :762

    Y. Komagata, S. Amonpatumrat, K. Sano, S. Kawashima, S. Kaname, Y. Arimura, A. Yamada

    
  • ·Antibodies to LAMP-2 alter lysosome function and attenuate chaperone-mediated autophagy in human macrophages

    Página :762

    K. Sintiprungrat, V. Thongboonkerd, P. Andrea, R. Kain, A.J. Rees

    
  • ·Urinary HMGB1 levels are associated with CD4+ T-cells in urine in patients with ANCA-associated vasculitis and active nephritis

    Página :762-763

    A.W. Silva De Souza, W.H. Abdulahad, J. Westra, P. Sosicka, P.C. Limburg, M. Bijl, C.A. Stegeman, C.G.M. Kallenberg

    Resumen Resumen Esquema Esquema
  • ·HMGB1 in ANCA-associated vasculitis: A longitudinal study

    Página :763

    A.W. Silva De Souza, J. Westra, J. Bijzet, P.C. Limburg, M. Bijl, C.A. Stegeman, C.G.M. Kallenberg

    
  • ·Functionally effect regulatory B cells in patients with active ANCA vasculitis

    Página :763

    L. Aybar, S. Hogan, J. Mcgregor, J. Vick, C. Poulton, Y. Hu, C. Henderson, R. Falk, D. Bunch

    
  • ·In vitro neutrophil activation by ANCA from patients with ANCA associated vasculitis; degranulation and oxidative burst

    Página :764

    S. Ohlsson, S. Ohlsson, L. Holm, L. Gunnarsson, T. Hellmark

    
  • ·Potential defect in annexin-A1-dependent anti-inflammatory mechanisms in GPA: Its cleavage by PR3 and its inhibition by autoantibodies

    Página :764

    M. Pederzoli-Ribeil, A. Regent, A. Millet, F. D’acquisto, L. Guillevin, M. Perretti, L. Mouthon, V. Witko-Sarsat

    
  • ·Thrombotic vasculopathy with neovascularisation associated with probably levamisole-contaminated cocaine: Report of 2 cases

    Página :764-765

    L.F. Flores-Suárez, M.A. Martínez-Velasco, S. Toussaint-Caire, A. Rodríguez-Carreón, M. Díaz-Lozano, K. Sánchez-Armendáriz

    Resumen Resumen Esquema Esquema  
  • ·Cutaneous hypersensitivity vasculitis associated with visceral Mycobacterium tuberculosis infection: A report of three cases

    Página :765

    M. Areses, C. Perez, J. Ibañez, M. Fanlo, M. Abinzano, M. Cia

    
  • ·Severe diffuse alveolar haemorrhage after TAVI with CoreValve in patient with AAV and Horton disease in remission. An immuno-allergic reaction?

    Página :765-766

    G.A. Gregorini, C. Fiorina, M.F. Bonetti

    Resumen Resumen Esquema Esquema
  • ·Microscopic vasculitis associated to Sjögren’s syndrome. About 4 cases

    Página :766

    I. Ben Ghorbel, N. Belfeki, T. Ben Salem, A. Hamzaoui, M. Khanfir, M. Lamloum, M. Miled, H. houman

    
  • ·Quantifying the effect of rituximab on changes in serum immunoglobulin G

    Página :766-767

    D. Roberts, R. Smith, R. Jones, F. Alberici, H. Marco, D. Jayne

    Resumen Resumen Esquema Esquema
  • ·Risk of malignancy with long-term immunosuppression in ANCA-associated vasculitis

    Página :767

    C. Rahmattulla, A. Göçeroğlu, M.E.J. Reinders, E.C. Hagen, J.A. Bruijn, I.M. Bajema

    
  • ·Infectious complications related to treatment in an inception cohort of antineutrophil cytoplasmic antibody associated vasculitis

    Página :767

    J. Mcgregor, R. Negrete-Lopez, C. Poulton, J. Kidd, S. Weaver, L. Goetz, Y. Hu, P. Nachman, R. Falk, S. Hogan

    
  • ·Cyclophosphamide effect on immunoglobulins levels in AAV patients treated with long-term pre-emptive rituximab maintenance

    Página :767-768

    E. Besada, W. Koldingsnes, J. Nossent

    Resumen Resumen Esquema Esquema
  • ·An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis (RITAZAREM)

    Página :768

    D. Jayne, R. Smith, P. Merkel

     
  • ·C5aR inhibitor on leukocytes exploratory ANCA associated renal vasculitis (CLEAR) clinical trial with orally administered CCX168

    Página :768-769

    A. Bruchfeld, M. Schaier, M. Jadoul, D. Selga, I. Szombati, M. Venning, P. Hamilton, K. Ciechanowski, C. Hugo, M. Segelmark, O. Viklicky, J. Jaen, T. Schall, P. Bekker

    Resumen Resumen Esquema Esquema
  • ·Lack of efficacy of tocilizumab in mucocutaneous Behçet’s syndrome: Report of two cases

    Página :769

    A.P. Diamantopoulos, G. Hatemi

    
  • ·Improving the quality and safety of intravenous cyclophosphamide (IV CYC): A regional audit of a best-practice protocol

    Página :769

    F. Rees, S. Varughese, M. Regan, K. Lim, C. Symonds, P. Lanyon

    
  • ·An open-label trial of abatacept in mild relapsing granulomatosis with polyangiitis (Wegener’s) (GPA)

    Página :770

    C. Langford, D. Cuthbertson, G. Hoffman, J. Krischer, C. Mc Alear, P. Monach, P. Seo, U. Specks, S. Ytterberg, P. Merkel

    
  • ·Lactoferrin inhibits formation of neutrophil extracellular traps in inflammation

    Página :770

    K. Okubo, M. Kamiya, Y. Urano, M. Nangaku, T. Fujita, J. Hirahashi

    
  • ·Incidence of coronary aneurysms in children with Kawasaki disease after early treatment with IVIG and aspirin: Report of 55 cases

    Página :771

    C. Romero, C. Perez, P. Martinez, R. Urabayen, P. Fanlo, T. Carrasquer

    
  • ·Co-trimoxazole monotherapy as induction therapy for localized granulomatosis with polyangiitis

    Página :771

    J. Tuin, J.S. Sanders, C.A. Stegeman

     
  • ·Successful treatment of refractory cutaneous ulcer associated with polyarteritis nodosa with bosentan

    Página :771-772

    P. Fanlo, L. Loidi, S. Clemos, A. Villanueva, E. Huarte, M. Mellado, T. Elias, C. Perez

    Resumen Resumen Esquema Esquema
  • ·Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: A randomized controlled trial. PEXIVAS

    Página :772

    B. Brezina, D. Jayne

    
  • ·Fixed-interval repeat dose rituximab improves abnormalities in the periperhal B cell compartment and reduces relapse rates in ANCA associated vasculitis

    Página :772

    E. Wallin, R. Smith, R. Jones, D. Jayne, K. Smith

    
  • ·Predictors of treatment resistance and relapse in Chinese patients with antineutrophil cytoplasmic antibody-associated disease

    Página :772-773

    Y. Cao

    Resumen Resumen Esquema Esquema
  • ·Induction treatment of ANCA associated vasculitis with a single dose of rituximab

    Página :773

    M. Little, T. Turner-Stokes, E. Sandhu, N. Stolagiewicz, C. Ashley, A. Salama, A. Burns, A. Howie, D. Dinneen

     
  • ·Therapeutic drug monitoring detects high interpatient variability in response to mycophenolic acid treatment in patients with ANCA-associated vasculitis

    Página :773-774

    M. Schaier, S. Bönisch-Schmidt, V. Schwenger, M. Zeier, C. Sommerer

    Resumen Resumen Esquema Esquema
  • ·Time to remission and relapse following rituximab in an inception cohort of antineutrophil cytoplasmic antibody associated vasculitis

    Página :774

    M.E. Studstill, J. Mcgregor, C. Poulton, Y. Hu, P. Nachman, R. Falk, S. Hogan

    
  • ·Rituximab use in patients with ANCA-associated vasculitis: Clinical efficacy and impact on immunological parameters

    Página :774

    Z. Chocova, Z. Hruskova, H. Mareckova, B. Svobodova, V. Bednarova, E. Jancova, R. Rysava, V. Tesar

    
  • ·Maintenance therapy using rituximab-induced continuous B cell depletion for ANCA vasculitis

    Página :774-775

    W. Pendergraft, F. Cortazar, J. Wenger, A. Murphy, K. Laliberte, J. Niles

    Resumen Resumen Esquema Esquema  
  • ·What everybody is doing but no one is talking about: Complementary and alternative medicine (CAM) prevalence in the ANCA SVV population

    Página :775

    E. Berg, J. Mcgregor, M. Burkart, C. Poulton, S. Hogan

    
  • ·Long term follow up of patients who received repeat dose rituximab as maintenance therapy for ANCA associated vasculitis (AAV)

    Página :775-776

    R. Smith, F. Alberici, R. Jones, D. Jayne

    Resumen Resumen Esquema Esquema
  • ·Re-treatment with rituximab in ANCA-associated vasculitis only in the presence of clinical relapse: A single centre experience

    Página :776

    G. Jeannin, C. Salviani, S. Possenti, A. Regazzoli, F. Allegri, G. Cancarini, G.A. Gregorini

    
  • ·Gestational rituximab exposure in women with vasculitis

    Página :776-777

    W. Pendergraft, M. Mcgrath, A. Murphy, P. Murphy, K. Laliberte, J. Niles

    Resumen Resumen Esquema Esquema
  • ·Use of rituximab in Hispanic patients with severe ANCA associated vasculitis: A 6 years experience in a tertiary centre in Chile

    Página :777

    F. Silva, L. Massardo, M. Mimica, P. Pastenes, M. Cisternas, F. Radrigan, M. Gutierrez

    
  • ·Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in Granulomatosis with Polyangiitis: Results from a single centre

    Página :777

    E. Besada, W. Koldingsnes, J. Nossent

    
  • ·Use of an empirically derived cyclophosphamide dosing nomogram for treatment of vasculitis

    Página :777-778

    A. Salama, M.D. Gabrel, A. Koteci, L. Harper, D. Jayne, D. Nitsch, R. Daniel, E. Naylor, M. Little

    Resumen Resumen Esquema Esquema
  • ·Retreatment with Rituximab in the RAVE Trial

    Página :778

    E. Miloslavsky, U. Specks, P. Merkel, P. Seo, R. Spiera, C. Langford, G. Hoffman, C. Kallenberg, W. St. Clair, N. Tchao, L. Ding, D. Ikle, B. Jepson, P. Brunetta, J. Stone

    
  • ·Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (MAINRITSAN): Follow-up at 34 months

    Página :778-779

    B. Terrier, C. Pagnoux, A. Karras, C. Khouatra, O. Aumaitre, P. Cohen, F. Maurier, O. Decaux, H. Desmurs-Clavel, P. Gobert, T. Quemeneur, C. Blanchard-Delaunay, P. Godmer, X. Puechal, L. Mouthon, L. Guillevin

    Resumen Resumen Esquema Esquema  
  • ·Safety of remission induction with rituximab versus cyclophosphamide in patients 65 and older with severe ANCA-associated vasculitis

    Página :779-780

    E. Miloslavsky, U. Specks, P. Merkel, P. Seo, R. Spiera, C. Langford, G. Hoffman, C. Kallenberg, W. St. Clair, N. Tchao, L. Ding, D. Ikle, B. Jepson, P. Brunetta, J. Stone

    Resumen Resumen Esquema Esquema

• Index des auteurs

  • ·Index auteurs

    Página :782-790

    Resumen Resumen Esquema Esquema